Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

Paolo A. Ascierto; Ester Simeone; Vanna Chiarion‐Sileni; Jacopo Pigozzo; Michele Maio; Maresa Altomonte; Michele Del Vecchio; Lorenza Di Guardo; Paolo Marchetti; Ruggero Ridolfi; Francesco Cognetti; Alessandro Testori; Maria Grazia Bernengo; Michele Guida; Riccardo Marconcini; Mario Mandalà; Carolina Cimminiello; Gaetana Rinaldi; Massimo Aglietta; Paola Queirolo

doi:10.1186/1479-5876-12-116

Keywords

IpilimumabMedicineInternal medicineAdverse effectNeuroblastoma RAS viral oncogene homologCohortClinical trialExpanded accessOncologyMelanomaCancerImmunotherapyCancer research

Affiliated Institutions

Related Publications

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).

Mario Sznol , Harriet M. Kluger , Margaret K. Callahan +17 more

LBA9003^ Background: We report updated survival and clinical activity in initially enrolled cohorts and activity by BRAF MT status in a phase I trial of concurrent and sequenced...

2014 Journal of Clinical Oncology 137 citations

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

Reinhard Dummer , Adil Daud , Igor Puzanov +18 more

2 and 10 mg/kg Q3W, respectively, over control (P<0.00001 for both comparisons). The 6-month PFS rate was 34% (95% CI 27%-41%) and 38% (95% CI 31%45%) for pembrolizumab 2 and 10...

2015 Journal of Translational Medicine 94 citations

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

Antoni Ribas , F. Stephen Hodi , Richard Kefford +17 more

LBA9000^ Background: The humanized monoclonal IgG4 anti-PD-1 antibody MK-3475 has demonstrated durable antitumor activity in MEL and NSCLC. We evaluated MK-3475 efficacy and saf...

2014 Journal of Clinical Oncology 130 citations

Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

Michele Maio , Jean‐Jacques Grob , Steinar Aamdal +9 more

Purpose There is evidence from nonrandomized studies that a proportion of ipilimumab-treated patients with advanced melanoma experience long-term survival. To demonstrate a long...

2015 Journal of Clinical Oncology 466 citations

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

Antoni Ribas , F. Stephen Hodi , Richard Kefford +17 more

LBA9000^ Background: The humanized monoclonal IgG4 anti-PD-1 antibody MK-3475 has demonstrated durable antitumor activity in MEL and NSCLC. We evaluated MK-3475 efficacy and saf...

2014 Journal of Clinical Oncology 54 citations

Publication Info

Year: 2014
Type: article
Volume: 12
Issue: 1
Pages: 116-116
Citations: 161
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

161

OpenAlex

Cite This

APA Style

                            
                                
                                    Paolo A. Ascierto, 
                                
                                    Ester Simeone, 
                                
                                    Vanna Chiarion‐Sileni
                                
                                et al.
                            
                            (2014). 
                            Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. 
                            Journal of Translational Medicine
                            , 12
                            (1)
                            , 116-116.
                            https://doi.org/10.1186/1479-5876-12-116
                        

Identifiers

DOI: 10.1186/1479-5876-12-116